Home Cart Sign in  
Chemical Structure| 1204313-51-8 Chemical Structure| 1204313-51-8

Structure of Icotinib HCl
CAS No.: 1204313-51-8

Chemical Structure| 1204313-51-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Icotinib HCl is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR (L858R), EGFR (L861Q), EGFR (T790M) and EGFR (T790M, L858R).

Synonyms: BPI-2009H; Icotinib Hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Icotinib HCl

CAS No. :1204313-51-8
Formula : C22H22ClN3O4
M.W : 427.88
SMILES Code : C#CC1=CC(NC2=C3C=C(OCCOCCOCCO4)C4=CC3=NC=N2)=CC=C1.[H]Cl
Synonyms :
BPI-2009H; Icotinib Hydrochloride
MDL No. :MFCD22124500

Safety of Icotinib HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Icotinib HCl

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03766490 Non-Small-Cell Lung Not Applicable Not yet recruiting December 20, 2020 China, Jangsu ... More >> The First Affiliated hospital of soochow university Not yet recruiting Suzhou, Jangsu, China Contact: Min Tao, Doctor Less <<
NCT02778893 NSCLC Phase 4 Recruiting March 2020 China, Henan ... More >> XZhang Recruiting Zhengzhou, Henan, China, 450000 Contact: zhang xiaoju    15837101166       Principal Investigator: zhang xiaoju Less <<
NCT01534585 Nasopharyngeal Carcinoma Phase 1 Phase 2 Completed - China, Zhejiang ... More >> Taizhou Hospital, Wenzhou Medical College Taizhou, Zhejiang, China, 317000 Less <<
NCT02934256 Vestibular Schwannoma ... More >> Neurofibromatosis Type 2 Less << Phase 2 Recruiting June 2018 China, Beijing ... More >> Beijing Tiantan Hospital Affiliated to Capital Medical University Recruiting Beijing, Beijing, China, 100050 Contact: Pinan Liu    +86 010 67096865    liupinan@hotmail.com    Principal Investigator: Fu Zhao          China Beijing Tiantan Hospital Affiliated to Capital Medical University Recruiting Beijing, China, 100050 Contact: Pinan Liu    +86 010 67096865    liupinan@hotmail.com    Principal Investigator: Fu Zhao Less <<
NCT02375022 Lung Cancer Phase 2 Unknown March 2016 China, Zhejiang ... More >> Zhejiang University Recruiting Hangzhou, Zhejiang, China, 310000 Contact: Qiong Zhao    0571-87236802    doczq.2008@gmail.com    Contact: Ling Peng    0571-87236800    Drpengling@gmail.com Less <<
NCT02574091 Psoriasis Phase 1 Completed - New Zealand ... More >> Christchurch Clinical Studies Trust Christchurch, New Zealand Less <<
NCT03222622 Mild to Moderate Psoriasis Phase 2 Terminated(The efficacy failed... More >> to meet the primary efficacy endpoint) Less << - China, Zhejiang ... More >> The Second Affiliated hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310009 Less <<
NCT01973725 Esophageal Squamous Cell Carci... More >>noma Less << Phase 2 Recruiting December 2018 China, Guangdong ... More >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Li Yuhong, MD       liyh@sysucc.org.cn    Principal Investigator: Li Yuhong, MD Less <<
NCT02033148 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Withdrawn(changes in study des... More >>ign by sponsor not acceptable for participating) Less << - -
NCT02801435 Psoriasis Phase 1 Completed - China, Zhejiang ... More >> The Second Affiliated hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310009 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.69mL

2.34mL

1.17mL

23.37mL

4.67mL

2.34mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories